These highlights do not include all the information needed to use Greer Standardized Mite Extracts safely and effectively. See full prescribing information for Greer Standardized Mite Extracts.Standardized Mite Extract (Dermatophagoides farinae) Standardi | Allergenic Extracts Standardized Mite [Greer Laboratories, Inc.] | BioPortfolio

12:32 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Greer Standardized Mite (Dermatophagoides farinae and/or Dermatophagoides pteronyssinus) Extracts are allergenic extracts indicated for

For immunotherapy, patients must show hypersensitivity to Dermatophagoides farinae (D. farinae) or Dermatophagoides pteronyssinus (D. pteronyssinus) based on their clinical history, allergen exposure history, and skin test reactivity.

Do not inject intravenously.

Greer Standardized Mite extracts are diluted with sterile diluent for allergenic extracts when used for intradermal testing or subcutaneous immunotherapy. Dosages vary by mode of administration, and by individual response and tolerance. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Greer Standardized Mite Extracts should be a light brown solution that is free of particulate matter. If particulate matter is observed then the solution should be discarded.

For diagnosis of a patient with a suspected allergy to either species of dust mite (D. farinae or D. pteronyssinus), diagnostic skin testing should include the standardized mite mixture or the single-species mite extracts.

2.1.1 Percutaneous Skin Testing

For percutaneous (scratch, prick, or puncture) testing, use 10,000 Allergy Units/mL Greer Standardized Mite Extract stock concentrate in dropper vials. If patient is suspected of having exquisite sensitivity, such as anaphylaxis, to certain foods and drugs, initiate percutaneous testing with several serial 10-fold dilutions of the usual test concentration.

When using percutaneous test devices, follow the directions provided with the test devices.

Include a positive control to detect false negative responses to skin testing, which may occur if serum levels of antihistamines remain from prior medication administration [see Drug Interactions (7.2) ]. A glycerinated histamine phosphate diluted to 10mg/mL (6mg/mLhistamine base) may be used as the positive control.

Include a negative control to detect false positive responses, which can occur when the patient has a non-specific reaction to the diluent. A 50% glycerosaline solution may be used as the negative control.

Read skin tests 15-20 minutes after exposure. Record the induration (wheal) and erythema (flare) response by noting the longest diameter of each, or by the sum of the longest erythema diameter and the mid-point orthogonal diameters of erythema (ΣE).

Percutaneous testing devices often have their own grading systems, as these devices may cause different degrees of trauma to the skin and deliver different volumes of allergenic extract. Follow grading instructions for the device used.

2.1.2 Intradermal Skin Testing

Intradermal tests are commonly used when the reaction to percutaneous testing is negative or equivocal but the patient has a strong clinical history of symptoms triggered by exposure to a specific allergen. Because immediate systemic reactions are more common with intradermal testing, prescreening with percutaneous testing is a practical safety measure.

Dilute the stock concentrate with sterile diluent. Use saline with human serum albumin (HSA), buffered saline, or saline. If prescreening is not done, or if patients are expected to be high risk, precautions should be observed since some patients have experienced anaphylaxis and death.

The mean dose of Greer dust mite allergen required to elicit a positive intradermal test result (ΣE ≥ 50 mm) in a total of 83 mite puncture test positive (ΣE ≥ 20 mm) persons is shown in Table 1.

Table 1. Intradermal Reactivity to Mite Allergens
Allergen Number of Persons Dose to Elicit 50 mm Sum of Diameter Erythema Reaction
Mean (AUAllergy Units/mL) Range (AU/mL)
D. farinae 46 0.00856 0.00004 – 1.75935
D. pteronyssinus 37 0.00570 0.00002 –1.36341Data is available on file with Greer

Subcutaneous injection only.

Subcutaneous injections for immunotherapy should be prepared by dilution of stock concentrate based on patient's reactivity. Stock concentrations of Greer Standardized Mite Extract are available in 5,000 Allergy Units/mL, 10,000 Allergy Units/mL, 30,000 Allergy Units/ mL for immunotherapy. See Table 2 for dilution preparation. Also see Dosage Modification Guidelines. (2.2.1)

2.2.1 Dosage Modifications Guidelines for Immunotherapy

The following conditions may indicate a need to withold or reduce the dosage of immunotherapy. In situations prompting dose reduction, once the reduced dose is tolerated, a cautious increase in dosage can be attempted.

Immunotherapy should be withheld or reduced in dosage if the following concurrent conditions exist:

Changing to a different lot of extract: All extracts lose potency over time. A fresh extract may have an effective potency that is substantially greater than that of older extracts. Therefore, the first dose from the fresh vial should not exceed a 25% increase of the previous dose or a 75% reduction of the previous dose, assuming both extracts contain comparable amounts of allergen, defined by Allergy Units.

Unscheduled Gaps between Treatments: Patients may lose tolerance for allergen injections during prolonged periods between doses, thus increasing their risk for an adverse reaction. The duration of tolerance between injections varies from patient to patient.

The extract previously used is from another manufacturer: Since manufacturing processes and sources of raw materials differ among manufacturers, the interchangeability of extracts from different manufacturers cannot be assured. The starting dose of the extract from a different manufacturer should be greatly decreased even though the extract is the same formula and dilution. In general, a dose reduction of 50-75% of the previous dose should be adequate, but each situation must be evaluated separately considering the patient's history of sensitivity, tolerance of previous injections, and other factors. Dose intervals should not exceed one week when rebuilding dose.

The previous extract has expired or is near expiry: The dating period for allergenic extracts indicates the time that they can be expected to remain potent under ideal storage conditions (2°-8°C) [see How Supplied/Storage and Handling (16) ]. Some loss of potency occurs even when stored under ideal conditions, therefore extracts should not be stored beyond the expiration date. Instead, a new lot of should be used (see "Changing to a different lot of extract", above)

Changing from non-stabilized to human serum albumin (HSA) stabilized diluents: Allergenic extracts diluted with HSA and 0.4% phenol are more potent than extracts diluted with diluents that do not contain stabilizers. When switching from a non-stabilized to an HSA stabilized diluent, consider lowering the dose for immunotherapy.

2.2.2 Administration of Immunotherapy

Administer immunotherapy by subcutaneous injection in the lateral aspect of the arm or thigh. Avoid injection directly into any blood vessel.

To prepare dilutions for intradermal testing and immunotherapy, start with a 5,000, 10,000, or 30,000 Allergy Units/mL stock concetrate, and prepare a 1:10 dilution by adding 0.5 mL of concentrate to 4.5 mL of sterile aqueous diluent. Subsequent dilutions are made in a similar manner (see Table 2).

Table 2. Ten-fold Dilution Series for intradermal testing and immunotherapy
Dilution Extract Diluent AUAllergy Units/mL AU/mL AU/mL
0 Concentrate 5,000 10,000 30,000
1 0.5 mL Concentrate 4.5 mL 500 1,000 3,000
2 0.5 mL Dilution 1 4.5 mL 50 100 300
3 0.5 mL Dilution 2 4.5 mL 5 10 30
4 0.5 mL Dilution 3 4.5 mL 0.5 1 3
5 0.5 mL Dilution 4 4.5 mL 0.05 0.1 0.3
6 0.5 mL Dilution 5 4.5 mL 0.005 0.01 0.03

For immunotherapy, concentrated extracts are diluted in normal saline, buffered saline, albumin saline or 10% glycerosaline. For intradermal testing extracts may be diluted in normal saline, buffered saline, or albumin saline.

Greer Standardized Mite Extract D. farinae and Greer Standardized Mite Extract D. pteronyssinus are supplied as stock concentrates containing 10,000 Allergy Unit/mL and Greer Standardized Mite Extract mixture (D. farinae and D. pteronyssinus) is supplied as a stock mixture concentrate containing 5,000 Allergy Units/mL of each species for use in percutaneous skin testing.

Greer Standardized Mite Extract D. farinae and Greer Standardized Mite Extract D. pteronyssinus are supplied as stock concentrates containing 5,000, 10,000, or 30,000 Allergy Unit/mL. Greer Standardized Mite Extract mixture (D. farinae and D. pteronyssinus) is supplied as a stock mixture concentrate containing 5,000 and 15,000 Allergy Units/mL of each species for use in intradermal testing and immunotherapy.


All concentrates of Greer Standardized Mite Extracts have the ability during skin testing and immunotherapy to elicit serious systemic reactions including anaphylactic shock and death [see Adverse Reactions (6) ].

A review of the literature indicates that the incidence of near-fatal reactions to immunotherapy, defined as severe respiratory compromise, hypotension, or both, and requiring emergency treatment with epinephrine, has been estimated as 5.4 events per million injections in a 10-year retrospective survey of allergists. Fatalities from immunotherapy injections have been estimated to occur at a rate of approximately one death per 2.0 to 2.8 million injections in 4-, 10- and 12-year retrospective surveys of allergists.

Because of the danger of serious reactions, caution is required in testing and treating high risk patients and those with medical conditions that reduce their ability to survive a serious systemic adverse event.

High-risk patients are defined as those patients:

High risk patients have had fatal reactions. In addition, patients not high-risk but on beta blockers have had fatal reactions because beta blockers interfere with beta adrenergics such as epinephrine used in treatment or anaphylaxis.

Patients should be kept under observation for a minimum of 30 minutes after receiving allergenic extracts so that any adverse reaction can be observed and properly handled.

Medications to treat systemic reactions, as well as emergency equipment should be available for immediate use. Extracts must only be administered by persons who are aware of the risk of systemic reactions, including anaphylaxis; are capable of handling such reactions; and have the necessary drugs and equipment on hand to do so.

Patients receiving beta blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including anaphylaxis. Inhalant allergy immunotherapy should be approached with caution in patients taking beta blockers. The risks of anaphylaxis in these patients should be carefully weighed against the benefits of immunotherapy [see Drug Interactions (7.1) ].

Immunotherapy should be given cautiously to patients with other immunologic diseases and only if the risk from exposure to the allergen is greater than the risk of exacerbating the underlying disorder.

Systemic reactions consist primarily of allergic symptoms, such as generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, and hypotension. Additional symptoms that are not usually associated with allergy also may occur, such as nausea, emesis, abdominal cramps, and diarrhea. Serious reactions may cause shock, loss of consciousness, and even death. Based on published studies, systemic reactions occur in less than 1% of patients receiving conventional immunotherapy to greater than 36% in some studies of patients receiving rush immunotherapy.

Local reactions at the injections site are the most commonly occurring reactions (e.g., erythema, itching, swelling, tenderness, pain). Although most adverse systemic reactions occur within 30 minutes of injection (some within minutes of extract exposure), such reactions also can occur up to six hours after skin tests or immunotherapy [see Dosage and Administration (2.2) ].

Patients receiving beta blocker drugs may not be responsive to beta adrenergic drugs used to treat anaphylaxis, and may wish to temporarily postpone treatment day of skin testing. All such decisions should be made in consultation with the physician. [see Warnings and Precautions (5.2) ].

Skin testing with allergenic extracts should not be performed within 2-3 days of first-generation H-histamine receptor blockers (e.g., clemastine, diphenhydramine) and within 3 to 10 days of second-generation antihistamines (e.g., loratadine, terfenadine), except for astemizole, which requires an interval of 30-60 days between allergenic extract exposure and use. These products suppress histamine skin test reactions and could mask a positive response.

Topical corticosteroids may suppress skin reactivity and should be discontinued at the skin test site for at least 2-3 weeks before skin testing. Topical local anesthetics may suppress flare responses and should be avoided at skin test sites.

Tricyclic antidepressants can have potent antihistamine effects and will affect skin testing. Since use of tricyclics may alter skin test results, dosing for both skin testing and immunotherapy should be done with caution. If tricyclic medication has been recently discontinued, allow 7-14 days prior to skin testing to obviate the antihistamine effect. The risk of anaphylaxis in these patients should be carefully weighed against the risks and benefits of stopping tricyclics.

The suppressive action of other drugs should be considered and emphasizes the need for a histamine positive-control test.

Pregnancy Category C: Animal reproduction studies have not been conducted with Greer Standardized Mite Extracts. It is also not known whether Greer Standardized Mite Extracts can cause fetal harm when administered to a pregnant woman or whether they can affect reproduction capacity. Standardized Mite Extracts should be given to a pregnant woman only if clearly needed.

Studies have not been performed in animals to determine whether extracts affect fertility in males or females, have teratogenic potential, or have other adverse affects on the fetus. Exercise caution in testing or treating pregnant females because a systemic reaction may cause maternal cardiovascular compromise leading to fetal distress with sequelae.

It is not known whether allergenic extracts or their antigens are excreted in human milk. Because many drugs are excreted in human milk, exercise caution when extracts are administered to a nursing woman.

No studies have systematically examined differences in response to immunotherapy among child and adult patients. Children appear to tolerate injections of allergenic extracts very well. Very young children (under age 5) can have difficulty cooperating with an immunotherapy program and for this reason, the physician should consider the benefits and risks of immunotherapy and indiviualize treatment in patients under the age of 5 years. [See Warnings and Precautions (5) ].

Clinical studies of Greer Standardized Mite Extract did not include sufficent numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. Other reported clinical experiences has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of concomitant disease or other drug therapy including beta blockers.

For all allergenic extracts the therapeutic dose varies per indiviual. If a dose exceeds the window for a particular patient this may be considered an overdose and the patient may experience anaphylaxis. Systemic reactions are uncommon after injection, but if the patient receives more extract than can be tolerated at that particular time, and begins to experience immediate hypersensitivity anaphylaxis, institute emergency treatment by trained personnel.

Overdosage may occur because of an error in the volume of extract or incorrect diluents injected. An overdose may also occur when, in addition to immunotherapy, the patient is exposed concomitantly to similar environmental allergens. In the event of a systemic reaction, the preparation of allergen and dosage schedule should be carefully reviewed.

Greer Standardized Mite (Dermatophagoides farinae and/or Dermatophagoides pteronyssinus) extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. Each vial contains 5,000, 10,0000 or 30,000 Allergy units/mL of sterile mite extract (D. farinae and/or D. pteronyssinus), 50% glycerin v/v, and 0.4% phenol (preservative). Inert ingredients include 0.50% sodium chloride for isotonicity and 0.25% sodium bicarbonate as a buffer.

For immunotherapy, concentrated extracts are diluted in normal saline, buffered saline, albumin saline or 10% glycerosaline based on patient's reactivity. For intradermal testing, extracts may be diluted in normal saline, buffered saline, or albumin saline.

Source materials for the extract are whole mite bodies. The mites are cultured, handled, and cleaned to remove at least 99% of the food medium. The medium containes no material of human origin.

The mite extract is standardized by comparison to a reference preparation supplied by the Center for Biologics Evaluation and Research of the FDA, labeled 10,000 Allergy Unit/mL. The relative potency of the extract is determined by ELISA inhibition compared to the FDA mite reference, and is labeled in Allergy Unit/mL.

Dust mites belonging to the genus Dermatophagoides are indoor allergens found in humid geographic locations worldwide. D. farinae and D. pteronyssinus occur widely with most homes in the United States coinhabited by both species.

The complete mechanisms of allergen immunotherapy are not clear and remain the subject of investigation. The allergic reaction is dependent on the presence of allergen-specific immunoglobulin E (IgE) antibodies that are bound to specific receptors on mast cells and basophils. The presence of IgE antibodies sensitizes these cells, and upon interaction with the appropriate allergens, histamine and other mediators are released which produce local or systemic responses in sensitive individuals, and characteristic symptoms of atopic diseases, such as allergic rhinitis and allergic asthma. Changes in serum antibody and T-lymphocyte responses resulting from immunotherapy have been demonstrated, and these changes often correlate closely with clinical (symptom) improvements. Specific mechanisms may vary depending on the nature of the allergic disease, the allergenic specificities of patients and populations, extract formulations, route of administration, dose and duration of treatment.

Subcutaneous administration of allergenic extracts is known to elicit numerous immunological changes that are both time and dose-dependent. Many of these changes appear to be related to (or a precursor to) improvements in symptoms and other clinical parameters, as noted above. Specific changes found after immunotherapy with dust mite extracts include significant increases in mite-specific IgG4 antibodies, interleukin-10-positive T cells, and several T-cell receptors, and significant decreases in serum nitric oxide, eosinophil catonic protein, interleukin-4-positive T cells and IgE-mediated basophil histamine release.

No studies in animals have been performed to evaluate carcinogenecity, mutagenicity or impairment of fertility.

The dust mites D. farinae and D. pteronyssinus are the major source of allergens in house dust. The efficacy of immunotherapy for Type I hypersensitivity (i.e. allergy) to airborne allergens including dust mite has been well established. Specifically, immunotherapy for allergic hypersensitivity to house dust mite allergens has been addressed in a 1995 Cochrane meta-analysis of 20 randomized, controlled trials of immunotherapy, and two subsequent updated Cochrane meta-analysis published in 1999 and 2003. In addition, efficacy for immunotherapy in rush or cluster protocols, in which the dose escalation is compressed over days or weeks, has also been demonstrated

Store dust mite extract at 2°-8 °C (36° to 46°F).

Keep dust mite extract at 2°-8 °C (36° to 46°F) during office use.

Dilutions of concentrated extract result in a glycerin content of less than 50% which results in reduced stability of the extracts. 1:100 dilutions should be kept no longer than a month, and more dilute solutions no more than a week. The potency of a dilution can be checked by skin test comparison to a fresh dilution of the extract on a known mite allergic individual.

Mite extracts in 50% Glycero-Coca solution are supplied as follows:

D. farinae:
NDC 22840-0033
5,000 Allergy Unit/mL, 10, 30, and 50 mL vials
D. farinae:
NDC 22840-0034
10,000 Allergy Unit/mL, 10, 30, and 50 mL vials
D. farinae:
NDC 22840-0038
30,000 Allergy Units/mL, 10, 30, and 50 mL vials
D. pteronyssinus
NDC 22840-0035
5,000 Allergy Unit/mL, 10, 30, and 50 mL vials
D. pteronyssinus:
NDC 22840-0036
10,000 Allergy Unit/mL, 10, 30, and 50 mL vials
D. pteronyssinus:
NDC 22840-0039
30,000 Allergy Unit/mL, 10, 30, and 50 mL vials
D. farinae/D. pteronyssinus mixture:
NDC 22840-0037
5,000 Allergy Unit/mL each species, 10, 30, and 50 mL vials
D. farinae/D. pteronyssinus mixture:
NDC 22840-0040
15,000 Allergy Unit/mL each species, 10, 30, and 50 mL vials
D. farinae:
NDC 22840-0034
10,000 Allergy Unit/mL, 5 mL percutaneous test vial
D. pteronyssinus:
NDC 22840-0036
10,000 Allergy Unit/mL, 5 mL percutaneous test vial
D. farinae/D. pteronyssinus mixture
NDC 22840-0037
5,000 Allergy Unit/mL each species, 5 mL percutaneous test vial

Instruct the patient to remain in the office for observation for a minumum of 30 minutes after an injection; longer, if deemed necessary for the individual.

Caution patients that reactions may occur more than 30 minutes after skin testing or an injection.

Instruct patient to recognize the following symptoms as adverse reactions and to immediately return to the office or immediately seek other medical attention if any of these symptoms occur following an injection.

PRINCIPAL DISPLAY PANEL - 5 mL/10,000 AU/mL Vial Label



NDC# 22840-0034-3CANADA DIN# 02231321


5 mL 10,000 AU/ML

See Package Insert for Doseand Route of Administration


Lenoir, NC 28645US. Lic. 308

41BLot: SAMPLEItem: GB64A02

Rx OnlyPres. 0.4% Phenol. Store at 2-8C.Contains 50% v/v Glycerin.

Exp. 12/20/13

PRINCIPAL DISPLAY PANEL - 10 mL/10,000 AU/mL Vial Label



NDC# 22840-0036-6CANADA DIN# 02231324


10 mL 10,000 AU/ML

See Package Insert for Doseand Route of Administration


Lenoir, NC 28645US. Lic. 308

1DLot: SAMPLEItem: GB70A04

Rx OnlyPres. 0.4% Phenol. Store at 2-8C.Contains 50% v/v Glycerin.

Exp. 12/20/13




NDC# 22840-0037-3CANADA DIN# 02231325


5 mL

See Package Insert for Doseand Route of Administration


Lenoir, NC 28645US. Lic. 308

42BLot: SAMPLEItem: GBO3A02

Rx OnlyPres. 0.4% Phenol. Store at 2-8C.Contains 50% v/v Glycerin.

Exp. 12/20/13




NDC# 22840-0040-9


50 mL

See Package Insert for Doseand Route of Administration


Lenoir, NC 28645US. Lic. 308

39BLot: SAMPLEItem: GBO3A11

Rx OnlyPres. 0.4% Phenol. Store at 2-8C.Contains 50% v/v Glycerin.

Exp. 12/20/13


Greer Laboratories, Inc.

Active Ingredients


Drugs and Medications [194 Associated Drugs and Medications listed on BioPortfolio]

House dust mite, dermatophagoides farinae [allermed laboratories, inc.]

ALLERGENIC EXTRACT Standardized Mite Dermatophagoides farinae Dermatophagoides pteronyssinus

Standardized mite dermatophagoides farinae [nelco laboratories, inc.]

Allergenic Extract

Cat pelt, standardized [alk-abello, inc.]

Standardized Cat Pelt

Cat hair, standardized [alk-abello, inc.]

Standardized Cat Hair

Cat hair [allermed laboratories, inc.]

ALLERGENIC EXTRACT Standardized Cat Hair

Clinical Trials [1195 Associated Clinical Trials listed on BioPortfolio]

Comparing Allergenic Effects of 3 German Cockroach Extracts in Adults

The purpose of this study is to test and compare the allergenic effects of three commercially available German cockroach allergen extracts in adults. Study hypothesis: The biological pote...

Biological Standardization of Allergen Extracts of Pollens of Betula Pendula, Phleum Pratense and Mite Extract of Dermatophagoides Pteronyssinus

Allergen extracts are complex mixtures of proteins and contain varying amounts of allergenic and non-allergenic components. Many factors such as the biovariability, differences in extracti...

Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma

This is an observational prospective multicenter clinical study, to evaluate the efficacy and safety of the treatment with Allergovac Poliplus subcutaneous immunotherapy (SCIT) with a mixt...

The Effect of Autologous Autovaccine in Patients With Allergy on House-Dust-Mite

House dust mite allergy is a common problem, resulting in asthma, chronic swelling of the eyes, and running nose. We test a possibility to immunize subjects sensitized against house dust m...

Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children

Asthma, the airway inflammatory disorder, is an important chronic disease in children. About 10~15% children are bothered with this. Allergens, such as house-dust mites (HDM), animal dande...

PubMed Articles [2187 Associated PubMed Articles listed on BioPortfolio]

The extract, the molecular allergen or both for the in vitro diagnosis of peach and peanut sensitization?

Identifying the target molecule in food allergies, helps to assess the risk of anaphylaxis in a patient. Lipid Transfer Protein is the most frequent cause of food allergies in the Mediterranean area. ...

Synergistic effect of Dermatophagoides pteronyssinus allergen and Escherichia coli lipopolysaccharide on human blood cells.

House dust mites Dermatophagoides pteronyssinus are the main source of major inhalatory allergens inducing inflammatory response. Mite extract contain both allergenic proteins and lipopolysaccharides ...

Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: A randomized trial in a pediatric population.

The efficacy and safety of 300 index of reactivity (IR) tablets of house dust mite (HDM) allergen extracts in Japanese pediatric (5-16 years old) patients with allergic rhinitis (AR) were assessed in ...

Allergen content in German cockroach extracts and sensitization profiles to a new expanded set of cockroach allergens determine in vitro extract potency for IgE reactivity.

Cockroach allergens are an important cause of IgE-mediated sensitization in inner-city asthmatics. However, cockroach extracts used for diagnosis and immunotherapy are not standardized.

An evaluation of veterinary allergen extract content and resultant canine intradermal threshold concentrations.

Limited information is available for dogs on threshold concentrations (TCs), and the protein composition of common allergenic extracts produced by different manufacturers.

Quick Search


Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

Drugs and Medication Quicklinks

Searches Linking to this Drug Record